Abstract
Background and objectives: In our study we aimed to investigate the effect of esmolol, lidocaine and fentanyl on P wave dispersion (Ppwd), QT and corrected QT (QTc) durations and hemodynamic responses to endotracheal intubation during propofol induction.

Methods: A total of eighty adult patients, American Society of Anesthesiologists (ASA) Physical Status I or II aged 18 to 60 years were included in this prospective, randomised, double-blind study. All patients had control electrocardiograms (ECGs) done before anesthesia induction. The patients were randomised into four equal groups. The control group (Group C) received saline 5 mL, the esmolol group (Group E) received esmolol 0.5 mg.kg⁻¹, the fentanyl group (Group F) received fentanyl 2 μg.kg⁻¹ and the lidocaine group (Group L) received lidocaine 1.5 mg.kg⁻¹ before...
Introduction

Anesthetic agents may display proarrhythmic and antiarrhythmic activity by inducing electrical activity through various mechanisms. Other than the anesthetic agents used, existing heart disease and other concomitant systemic diseases, laryngoscopy and tracheal intubation, surgical manipulation, procedures performed on the patient, and medication may also cause arrhythmia in the intraoperative period. These effects can be determined on 12-lead electrocardiograms (ECGs) by measuring P-wave dispersion (Ppwd) and QT and corrected QT (QTc) intervals. Ppwd is defined as the difference between the maximum and minimum P-wave duration in 12 leads of surface ECGs. Ppwd is simple and non-invasive indicator of atrial arrhythmia such as atrial flutter or atrial fibrillation. Increased Ppwd is accepted as a predictor of postoperative atrial fibrillation after coronary artery surgery. QT and QTc intervals are electrocardiographic indicators of ventricular repolarization. Prolongation of the QTc interval is associated with an increased risk of ventricular arrhythmias such as torse de pointes.

Previous studies demonstrated that Ppwd and QTc intervals might be extended in conditions such as diabetes mellitus, hypertension, malnutrition, subarachnoid hemorrhage, obesity and metabolic syndrome. Also Ppwd and QTc intervals extended after laryngoscopy and tracheal intubation. For this reason, in patients with prolonged Ppwd and QTc interval, choice of anesthetic and adjuvant drugs is important.

The effects of esmolol, lidocaine and fentanyl on P-wave dispersion (Ppwd), QT and corrected QT (QTc) durations and hemodynamic responses to endotracheal intubation during propofol induction.

Methods

This prospective randomized study was conducted in May-November 2009 at Zonguldak Karaelmas University’s School of Medicine Research and Practice Hospital, Department of Anesthesiology and Reanimation after obtaining the approval of the Hospital Ethics Board (date 05.22.2008, number: 2008/07, President Dr. EY Sipahi) and patient consents.

Patients

After obtaining the approval from the hospital ethics committee, we enrolled 80 adult patients aged 18-60 years, with American Society of Anesthesiologists (ASA) Physical Status (PS) I and II, who were scheduled for elective non-cardiac surgery. Written informed consent was obtained from all participants. Age; ASA PS; serum sodium, potassium, calcium, chloride and magnesium levels; and body mass index (BMI) were recorded. Thirty minutes prior to anesthesia induction, all patients were premedicated with intramuscular 0.07 mg/kg midazolam (Dormicum; Roche, Basel, Switzerland). In the operating theatre, a 20-gauge cannula was used for intravenous access and 5-7 mL/kg Ringer’s Lactate (Ringer Laktat; Polifarma, Istanbul, Turkey) infusion was started.

Baseline arterial blood pressure, peripheral oxygen saturation, and ECG records were obtained. All patients were subjected to standard 12-lead ECG using a Hewlett Packard PageWriter 300pi ECG device (Andover, MA, USA), and control ECGs were recorded at a paper speed of 50 mm/sec with an amplitude of 1 mV/cm prior to anesthesia induction. After ECGs were recorded, patients were randomly divided into four groups using a random samples table.
**Exclusion criteria**

Exclusion criteria were: pregnancy, anorexia (BMI < 18 kg.m⁻²), obesity (BMI > 30 kg.m⁻²), chronic liver and kidney diseases, electrolyte disorders, diabetes mellitus, hypothyroidism or hyperthyroidism, alcohol addiction, coronary artery disease, Chagas disease, cardiomyopathy, arterial hypertension, atrial and/or ventricular hypertrophy on ECG, arrhythmia, cardiomegaly, valvular disease, cardiac insufficiency, and use of medication that led to extended QT intervals 1,5,6,15.

**Anesthesia induction**

In the control group (n = 20), patients previously received 5 ml saline bolus, followed by a continuous infusion of saline. Anesthesia was induced by intravenous 2.5 mg.kg⁻¹ propofol (Propofol 1% Fresenius; Fresenius Kabi, Uppsala, Sweden) 1.

In the lidocaine group (n = 20), patients previously received a bolus dose of lidocaine 1.5 mg.kg⁻¹, followed by a continuous infusion at 1.5 mg.kg⁻¹.h⁻¹. Next, anesthesia was induced intravenously with 2.5 mg.kg⁻¹ propofol (Propofol 1% Fresenius; Fresenius Kabi, Uppsala, Sweden) 1,19.

In the fentanyl group (n = 20), patients previously received a bolus dose of fentanyl 2 μg.kg⁻¹, followed by a continuous infusion at 1 μg.kg⁻¹.h⁻¹. Next, anesthesia was induced intravenously with 2.5 mg.kg⁻¹ propofol (Propofol 1% Fresenius; Fresenius Kabi, Uppsala, Sweden) 1,19.

In the esmolol group (n = 20), patients previously received a bolus dose of esmolol 0.5 mg.kg⁻¹, followed by a continuous infusion at 100 μg.kg⁻¹.h⁻¹. Next, anesthesia was induced intravenously with 2.5 mg.kg⁻¹ propofol (Propofol 1% Fresenius; Fresenius Kabi, Uppsala, Sweden) 1,20.

All of the groups received 6 mg.kg⁻¹.h⁻¹ propofol infusion for anesthesia maintenance 1,21.

All groups received 0.1 mg.kg⁻¹ vecuronium for muscle relaxation at the 3rd minute of induction 1. Intubation was performed at 3 minutes after vecuronium administration. Throughout the entire study, a 60/40% oxygen/air mixture was used as carrier gas. Patients were ventilated with end-tidal CO₂ at 35-40 mm Hg. We planned to administer intravenous 0.5 mg atropine (Atropin, Biofarma, Istanbul, Turkey) to patients with heart rate <50 beats.min⁻¹, and 5 mg ephedrine (Efedrin, Osel, Istanbul, Turkey) to those with mean arterial blood pressure < 30% of the control level for a minimum of 1 minute 1.

ECGs were recorded during the 1st and 3rd minutes during anesthesia induction and 3 minutes after administration of muscle relaxant. Intubation was performed with a tube of appropriate size, and further ECGs were recorded at 5 and 10 minutes, respectively. We recorded heart rate (HR), mean blood pressure, peripheral oxygen saturation (SpO₂), and end-tidal carbon dioxide (ETCO₂) during the 1st and 3rd minute during anesthesia induction, 3 minutes after administration of muscle relaxant, and 1, 2, 3, 4, 5 and 10 minutes after intubation. Surgery began after obtaining values at 10 minutes post-intubation 1.

**Electrocardiography Analysis:** Standard 12 derivation ECG recordings obtained from patients participating in the study with a paper speed of 50 mm.sec⁻¹ and a deflection of 1 mm.mV⁻¹ were analyzed (Hewlett Packard®, Pagewriter 300pi). Heart rate was calculated using mean RR time 1,5,6,15.

**Analysis of P-wave dispersion:** The beginning of P-wave was defined as positive deflection from the isoelectric line, and the end as the point when the positive deflection returned to the isoelectric line. We excluded from the study any derivations where the beginning and end of P-waves were not obvious. Pwd was the difference between the longest and shortest P-wave durations 1,5,6,15.

**Analysis of QT, QTc duration:** The QT interval was defined as between the beginning of QRS complex and the point where T waves descend onto the TP isoelectric line. When a U wave interrupted the T wave before returning to baseline, the QT interval was measured to the nadir of the curve between the T and U waves 1,5,6. The corrected QT interval (QTc) was calculated using the Bazett formula; QTc (ms)=QT measured /RR (where RR is the RR interval) 1,5,6,15.

Subjects who had less than 9 derivations assessed on the ECG were excluded from the study. All ECG measurements were evaluated three times by two experts who were not aware of the group allocation 1,5,6,15.

**Sample size calculation:** Our primary endpoint was the P wave dispersion duration changes after intubation. Sample size estimation was based on the study performed by Acampa et al. 22. In order to detect a 20% change in Pwd duration (34 ± 6.1 msec control values in Acampa’s study 22), with an α error of 0.05 and a power of 90%, we calculated that sample size should be at least 17 patients per group. Estimating an approximate 20% dropout rate, we included 20 patients in each group. The sample size estimation was performed using Power Calculator (http://www.dssresearch.com/KnowledgeCenter/toolkitcalculators/samplesizecalculators.aspx).

**Statistical analysis:** Statistical analyses were performed by using the Statistical Package for the Social Sciences (SPSS) version 16.0 for Windows (SPSS Inc., Chicago, IL, USA). Descriptive statistics included arithmetic means ± standard deviation (SD) for numerical data, and numbers and percentages for categorical data. The Kolmogorov-Smirnov test was used to examine compatibility between measured variables and normal distribution. Mann-Whitney U test was used to compare the averages of data with continuous measures such as: serum sodium, potassium, calcium, chloride and magnesium values; Pwd; QT and QTc durations; and HR, mean arterial pressure, ETCO₂ and SpO₂ values. The Wilcoxon Signed Ranks Test was used to compare intragroup repeated measures, and the x² test was used to compare data that denoted frequency, such as sex and ASA risk category. A p value < 0.05 after Bonferroni correction (p < 0.0083) was considered significant.

**Results**

Our subjects were allocated randomly into four groups. The groups were similar in terms of ASA risk category, age, sex, height, weight, and serum sodium, potassium, calcium, chloride and magnesium levels (p>0.0083) (Tables 1 and 2).

**Heart rate changes**

There were no significant differences between the control HR values of the groups (p > 0.0083) (Figure 1). Mean HR changes between Group C and Groups L, F did not have significant difference (p > 0.0083) (Figure 1). When Groups E and C
Table 1 Demographic and anthropometric data.

<table>
<thead>
<tr>
<th></th>
<th>Group C (n = 20)</th>
<th>Group L (n = 20)</th>
<th>Group F (n = 20)</th>
<th>Group E (n = 20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year)</td>
<td>33.75 ± 10.65</td>
<td>34.50 ± 9.97</td>
<td>35.25 ± 6.31</td>
<td>34.70 ± 6.23</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>75.40 ± 9.89</td>
<td>74.50 ± 9.54</td>
<td>75.85 ± 8.45</td>
<td>73.90 ± 10.34</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>170.10 ± 8.57</td>
<td>169.55 ± 8.00</td>
<td>169.00 ± 6.04</td>
<td>170.90 ± 7.62</td>
</tr>
<tr>
<td>ASA (n, %)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>17 (85%)</td>
<td>15 (75%)</td>
<td>16 (80%)</td>
<td>15 (75%)</td>
</tr>
<tr>
<td>II</td>
<td>3 (15%)</td>
<td>5 (25%)</td>
<td>4 (20%)</td>
<td>5 (25%)</td>
</tr>
<tr>
<td>Gender (n, %)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>9 (45%)</td>
<td>9 (45%)</td>
<td>8 (40%)</td>
<td>8 (40%)</td>
</tr>
<tr>
<td>M</td>
<td>11 (55%)</td>
<td>11 (55%)</td>
<td>12 (60%)</td>
<td>12 (60%)</td>
</tr>
</tbody>
</table>


Table 2 Biochemical data of groups.

<table>
<thead>
<tr>
<th></th>
<th>Normal values</th>
<th>Group C (n = 20)</th>
<th>Group L (n = 20)</th>
<th>Group F (n = 20)</th>
<th>Group E (n = 20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium (mmol.L⁻¹)</td>
<td>136–145</td>
<td>143.10 ± 3.17</td>
<td>142.95 ± 2.39</td>
<td>143.05 ± 1.95</td>
<td>144.50 ± 1.79</td>
</tr>
<tr>
<td>Potassium (mmol.L⁻¹)</td>
<td>3.5–5.5</td>
<td>4.43 ± 0.46</td>
<td>4.37 ± 0.42</td>
<td>4.56 ± 0.34</td>
<td>4.45 ± 0.32</td>
</tr>
<tr>
<td>Chlorine (mmol.L⁻¹)</td>
<td>98–110</td>
<td>104.38 ± 3.18</td>
<td>105.30 ± 3.14</td>
<td>105.93 ± 2.89</td>
<td>106.03 ± 2.69</td>
</tr>
<tr>
<td>Calcium (mg.dL⁻¹)</td>
<td>8.4–10.2</td>
<td>9.37 ± 0.51</td>
<td>9.23 ± 0.46</td>
<td>9.36 ± 0.42</td>
<td>9.52 ± 0.43</td>
</tr>
<tr>
<td>Magnesium (mg.dL⁻¹)</td>
<td>1.3–2.7</td>
<td>2.14 ± 0.19</td>
<td>2.12 ± 0.17</td>
<td>2.06 ± 0.07</td>
<td>2.16 ± 0.17</td>
</tr>
</tbody>
</table>

Figure 1 Changes in HR (beat.min⁻¹).
P1 = Control, P2 = 1 minute after anesthesia induction; P3 = 3 minutes after anesthesia induction; P4 = 1 minute after administration of muscle relaxant; P5 = 3 minutes after administration of muscle relaxant; P6 = 1 minute after endotracheal intubation; P7 = 2 minutes after endotracheal intubation; P8 = 3 minutes after endotracheal intubation; P9 = 4 minutes after endotracheal intubation; P10 = 10 minutes after endotracheal intubation.
*: p < 0.0083 between Group C and Group E; †: p < 0.0083 between Group L and Group E; ‡: p < 0.0083 between control value in Group C; §: p < 0.0083 between control value in Group L; ¶: p < 0.0083 between control value in Group F; ‖: p < 0.0083 between control value in Group E.
Effects of esmolol, lidocaine and fentanyl on P wave dispersion, QT, QTc intervals and hemodynamic responses to endotracheal intubation during propofol induction: a comparative study

were compared in terms of HR values, Group E had lower HR values at 1, 2, 3 and 4 min after the intubation (p < 0.0083). In addition, Group E had lower HR values at 3, 4 and 5 min after intubation in comparison with group L (p < 0.0083) (Figure 1).

Intra-group analysis of Group C has revealed that HR values, 1 and 3 min after the induction, 1, 2 and 3 min after the intubation were lower than the control HR value whereas 1, 2 and 3 min after the intubation were higher than the control HR (p < 0.0083) (Figure 1).

HR values of Group L, at the 1st and 2nd min after intubation were higher than the control value (p < 0.0083). HR values of Group F, at the 3rd min after the induction and 1st and 3rd after neuromuscular blockade were lower than the control value (p < 0.0083). HR values of Group E, at minute 3 after the induction, 1 and 3 min after neuromuscular blockade and 10 min after intubation were lower than the control value (p < 0.0083) (Figure 1).

**Mean blood pressure changes**

Basal mean arterial blood pressure values did not differ significantly among the groups (p > 0.0083). Groups L and F did not have significant mean blood pressure changes in comparison with Group C (p < 0.0083) (Figure 2).

Mean arterial blood pressure values at 2, 3 and 4 min after the intubation were lower in Group E in comparison with Group C (p < 0.0083) (Figure 2).

When the groups were compared between themselves, mean MAP values at 1 and 3 min after induction and neuromuscular blockade, 10 min after the intubation were lower than control MAP values, whereas the MAP value at 1 min post-intubation was higher than the control value (p < 0.0083) (Figure 2).

In Group L, the control MAP value was significantly lower than the MAP values at 1 and 3 min after induction, 1 min after neuromuscular blockade administration, 5 and 10 min after the intubation (p < 0.0083). In Group F, control MAP value was significantly lower than the MAP values at 1 and 3 min after induction and neuromuscular blockade administration, 4, 5 and 10 min after the intubation (p < 0.0083). In Group E, control MAP value was significantly lower than the MAP values at 1 and 3 min after induction and neuromuscular blockade administration, 3, 4, 5 and 10 min after the intubation (p < 0.0083) (Figure 2).

**Changes in SpO2 vs. ETCO2**

Intragroup and intergroup statistical analysis revealed no significant difference in relation to SpO2 and ETCO2 (p > 0.0083).

**Electrocardiographic changes**

All patients included in the study had sinus rhythm. No patients had atrioventricular or bundlebranch block, atrial or ventricular premature beat, tachyarrhythmia or bradyarrhythmia. When ECG records were analyzed, no significant difference was observed in terms of PR interval variations between and within the groups (p > 0.0083).

**Changes in P wave dispersion**

Control ECG records were similar in terms of Pwd duration (p > 0.0083) (Figure 3).

Pwd durations did not differ significantly between Group L, F and Group C at any measurement time (p > 0.0083). Measured Pwd values 5 and 10 min after the intubation in Group E were significantly lower than in Group C (p < 0.0083) (Figure 3).

![Figure 2 Changes in MAP (mm Hg).](image)
P1 = Control, P2 = 1 minute after anesthesia induction; P3 = 3 minutes after anesthesia induction; P4 = 1 minute after administration of muscle relaxant; P5 = 3 minutes after administration of muscle relaxant; P6 = 1 minute after endotracheal intubation; P7 = 2 minutes after endotracheal intubation; P8 = 3 minutes after endotracheal intubation; P9 = 4 minutes after endotracheal intubation; P10 = 10 minutes after endotracheal intubation

*: p < 0.0083 between Group C and Group E; ‡: p < 0.0083 between control value in Group C; §: p < 0.0083 between control value in Group L; ¶: p < 0.0083 between control value in Group E.
Figure 3 - Changes in Pwd (msec).
T1 = Control, T2 = 1 minute after anesthesia induction; T3 = 3 minutes after anesthesia induction; T4 = 3 minutes after administration of muscle relaxant; T5 = 5 minutes after endotracheal intubation; T6 = 10 minutes after endotracheal intubation.
*: p < 0.0083 between Group C and Group E; ‡: p < 0.0083 between control value in Group C.

Figure 4 - Changes in QTc interval (msec).
T1 = Control, T2 = 1 minute after anesthesia induction; T3 = 3 minutes after anesthesia induction; T4 = 3 minutes after administration of muscle relaxant; T5 = 5 minutes after endotracheal intubation; T6 = 10 minutes after endotracheal intubation.
*: p < 0.0083 between Group C and Group E; **: p < 0.0083 between Group C and Group F; ‡: p < 0.0083 between control value in Group C; ||: p < 0.0083 between control value in Group F.
When the groups were compared within themselves, while there were no significant difference in Pwd durations between the Pwd durations of control and all measurement times (p > 0.0083), Pwd durations at 5 and 10 minutes after the intubation were longer than control Pwd duration in Group C (p < 0.0083) (Figure 3).

**Changes in QTc duration**

Groups were similar in terms of QTc duration at the control ECG records (p > 0.0083). Group L and Group C did not have significant difference in terms of QTc durations (p > 0.0083) (Figure 4).

QTc duration measured 1 min after the induction in Group F was significantly shorter than in Group C (p < 0.0083). Measured QTc durations 1 min after the induction and 5 min after the intubation in Group E were significantly shorter than in Group C (p < 0.0083) (Figure 4).

When the Groups were compared within themselves, QTc durations 1 min after the induction and 5 min after the intubation were significantly longer than the QTc duration in Group C (p < 0.0083). Measured QTc duration 1 min after the induction in Group F was significantly shorter than the control QTc duration (p < 0.0083) (Figure 4).

Although Group L had shortening after the induction but prolongation in QTc durations after the intubation, QTc durations at all measurement times did not differ significantly compared with the control value. (p > 0.0083). In the same manner, QTc durations at all measurement times did not differ significantly either when compared with the control value in Group E. (p > 0.0083).

**Discussion**

As a result of this prospective, randomised, double-blinded study on the effects of lidocaine, fentanyl and esmolol on the hemodynamic and electrocardiographic changes secondary to intubation, we have determined that esmolol had protective effects for tachycardia, increase of MAP and prolongation of Pwd, QTc durations.

Important increase can occur in arterial blood pressure, HR, and plasma catecholamine concentrations during laryngoscopy and endotracheal intubation. Increase in hemodynamic parameters may lead to myocardial ischemia, infarction, arrhythmia and cerebral hemorrhage in patients with coronary heart disease, hypertension or cerebral vascular disease.

Prys-Roberts et al, has reported that reflex tachycardia and hypertension secondary to different but consecutive stimuli manifest themselves during laryngoscopy, increase with intubation and are rapidly resolved when the endotracheal tube is placed and laryngoscopy is withdrawn; nonetheless, concomitant arrhythmias continue.

Previous studies aiming to suppress hemodynamic responses accompanying laryngoscopy and tracheal intubation have defined utilization of glosopharyngeal and superior laryngeal nerve blocks, topical or systemic lidocaine, deep levels of anesthesia with intravenous or inhalational anesthesia, opioids, magnesium sulphate, vasodilators, calcium channel, α or β adrenergic receptor blockers,

On the other hand, studies comparing lidocaine, fentanyl and esmolol to suppress hemodynamic responses to intubation are limited.

In their study, Helfman et al. had given 200 mg lidocaine, 200 μg or 150 mg esmolol before anesthesia and induced it with 4-6 mg.kg⁻¹ thiopental, 1-1.5 mg.kg⁻¹ succinylcholine. They concluded that all three drugs were effective to block the increase in systolic blood pressure when compared to placebo. Additionally, researchers have reported that only the esmolol group had provided a stable and reliable protection against the increase in HR and systolic blood pressure.

Feng et al. have compared the hemodynamic effects of 2 mg.kg⁻¹ lidocaine, 3 μg.kg⁻¹ fentanyl or 2 mg.kg⁻¹ esmolol administration before anesthesia induction with 5 mg.kg⁻¹ thiopental and 1.5 mg.kg⁻¹ succinylcholine. They have concluded that only esmolol has prevented the increase in both HR and blood pressure related to intubation. They reported that fentanyl was able to suppress increase in blood pressure but not the HR, whereas lidocaine was unable to suppress the response to laryngoscopy.

Ugur et al. in their similar study, compared 1.5 mg.kg⁻¹ esmolol, 1 μg.kg⁻¹ fentanyl and 1.5 mg.kg⁻¹ lidocaine with respect to the hemodynamic responses to intubation. They concluded that esmolol administered 2 minutes before intubation was the most effective agent in preventing HR and rate-pressure product increase.

In the current study, we determined that esmolol was the most efficient agent to depress the reflex response to laryngoscopy and tracheal intubation, in parallel with previous studies.

Prolonged QT interval may cause arrhythmias such as polymorphic ventricular tachycardia or ventricular fibrillation. As QT interval changes along with heart rate - extending with bradycardia and shortening with tachycardia - independently of other factors, we found corrected QT interval according to heart rate interval (QTc). Even though a QTc interval of 440 milliseconds is considered prolonged, serious arrhythmias generally occur with a QTc interval of 600 milliseconds or longer. Prolonged QRS duration and increased dispersion of repolarization had been demonstrated to increase the risk of arrhythmic cardiac death in coronary artery disease patients. Therefore, prevention of the increase in HR, MAP, Pwd and QTc durations are important priorities for the induction of anesthesia in patients with prolonged QT, QTc, Pwd durations.

Previous studies demonstrated that QTc interval might be extended in conditions such as diabetes mellitus, prehypertension, subarachnoid hemorrhage, malnutrition, obesity and metabolic syndrome. QTc intervals also extend after laryngoscopy and tracheal intubation. Therefore, in patients with prolonged QTc interval, the choice of anesthetic and adjuvant drugs is important. Previously, it was demonstrated that inhalation anesthetic agents such as desflurane, sevoflurane, isoflurane, enflurane or halothane, extend the QTc interval duration. Despite the fact that etomidate and midazolam have no effects on the ventricle repolarization, they are not popular drugs for anesthesia induction. Propofol as an intravenous anesthetic agent is a popular choice for anesthesia induction in patients with prolonged QT, QTc, and Pwd interval, since it causes minimal prolongation of QT, QTc, and Pwd interval.
the present study, we used propofol as an induction agent and choose a muscle relaxant with minimal cardiovascular side effects. It is known that, laryngoscopy and tracheal intubation significantly increase the QTc duration. Previous studies demonstrated that, esmolol, lidocaine and fentanyl attenuated QTc interval prolongation associated with tracheal intubation. However, studies regarding the comparative effect of lidocaine, fentanyl and esmolol on QTc duration during laryngoscopy and tracheal intubation are limited. Although QTc intervals after the intubation and laryngoscopy did not present a significant difference between lidocaine, fentanyl and esmolol groups in the present study, when the results are compared to the control group, the most effective agent to prevent QTc prolongation after the intubation was found to be esmolol.

It is known that lidocaine’s effect on cardiomyocytes is inadequate to prevent heart repolarization. Due to its anti-arrhythmic characteristics, lidocaine is used in the treatment of heart rate disturbances of ventricular origin. In an earlier study researching the effect of lidocaine on QTc interval prolongation associated with tracheal intubation, researchers speculated that this effect of lidocaine could be associated with protective activation of the sympathetic system secondary to airway manipulation and, thus, inhibition of the prolonged repolarization. However, literature on this matter is confounding. Other studies demonstrated that lidocaine administration before intubation was unable to suppress the laryngoscopy and intubation-related sympathetic activity. In addition, significant MAP increases were observed in lidocaine groups after intubation in Owczuk et al.’s study, which raises the possibility of insufficient lidocaine efficacy in inhibiting sympathetic activation.

The previous studies on fentanyl for QTc interval are controversial. Wilton et al. reported that fentanyl is associated with a decrease in the QTc interval in a patient with long QT syndrome. However another study on this topic demonstrated QTc interval prolongation after fentanyl injection in patients undergoing coronary artery bypass graft operation.

It is known that beta-blockers, such as metoprolol, atenolol, reduce the cardiovascular response to sympathetic stimulation and therefore, could prevent arrhythmias. Beta-blockers’ anti-sympathetic and anti-ischemic effect can cause QTc duration decrease. Erdil et al. and Korpinnen et al. reported that esmolol shortens the QTc interval after the laryngoscopy and intubation. However, other studies reported that esmolol prevented the prolongation of the QTc interval following the administration of intravenous anesthetic agents, but not following laryngoscopy and intubation.

On the other hand, the administration of esmolol may produce a clinically significant reduction in HR and MAP. These effects may cause hemodynamic depression, which may lead to increased myocardial ischemia in susceptible patients, especially in combination with anesthesia induction agents. However, we did not observe any hemodynamic hazard associated with esmolol.

We believe the differences among the studies can be attributed to patients’ gender distribution, premedication status, and the use of different induction and adjuvant drugs in the anesthesia induction and maintenance periods. Anesthetic substances may affect P wave dispersion (PWD). The general anesthetic sevoflurane has been reported to prolong PWD, while desflurane has no effect on it, and propofol shortens it. PWD intervals also extend after laryngoscopy and tracheal intubation. However, to the best of our knowledge, there is no data about evaluating the effect of lidocaine, fentanyl and esmolol on prolonged PWD due to laryngoscopy and tracheal intubation.

We have determined that PWD was prolonged in the control group following laryngoscopy and tracheal intubation. Although PWD durations were prolonged after the intubation in lidocaine and fentanyl groups, when compared to control value PWD durations did not increase significantly in either group. In contrary, PWD durations after intubation were significantly different between the control and esmolol groups. Therefore, only esmolol suppresses the prolongation in PWD duration after intubation. Studies have demonstrated that f block agents like nebivolol, atenolol and metoprolol returned PWD duration to normal values in the event that it is prolonged due to various reasons. However, most of these agents are not available in intravenous form in order to use at anesthesia induction, second, esmolol has the shortest elimination half-life among them making it a very suitable agent for procedures with a brief duration.

One of the limitations of our study is the manual calculation of PWD on paper ECG. Also, we only searched PWD, QT, and QTc changes at induction of anesthesia. Therefore, it might be better if future studies include the whole perioperative process with Holter monitoring, which would probably document any increased rate of atrial and ventricular arrhythmias due to its higher quality.

We conclude that administration of esmolol before intubation prevents tachycardia and an increase in MAP, PWD and QTc durations caused by laryngoscopy and tracheal intubation. Esmolol should be used for anesthesia induction in patients with a predisposition to preoperative arrhythmias, and in those whose PWD and QTc durations are prolonged on their preoperative ECGs.

References
Effects of esmolol, lidocaine and fentanyl on P wave dispersion, QT, QTc intervals and hemodynamic responses to endotracheal intubation during propofol induction: a comparative study


30. Tan PH, Yang LC, Shih HC - Combined use of esmolol and nicardipine to blunt the hemodynamic changes following laryngoscopy and tracheal intubation. Anaesthesia. 2002;57:1195-212.


